Virginia Commonwealth University

VCU Massey Cancer Center

Clinical news

Novel combination therapy developed at Massey shows strong response in patients with advanced solid tumors

A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors. Approximately 61 percent of these patients experienced some degree of tumor growth delay, with multiple partial responses and one complete response. A phase 2 study testing the same combination of the drugs sorafenib and pemetrexed in patients with recurrent or metastatic triple negative breast cancer is now open at Massey. 

Continue reading →

Massey Physicians named Richmond Magazine’s Top Docs 2016

VCU Massey Cancer Center physicians again were recognized in Richmond Magazine’s annual list of “Top Docs.” Featured in the magazine’s April 2016 issue, the list includes 31 doctors from varied specialties who provide oncology-related care to Massey’s patients, including 10 who care for pediatric patients at the Children’s Hospital of Richmond at VCU. The selections were the result of a survey that asked Richmond-area physicians who they would recommend in a range of specialties.

Continue reading →

Massey opens clinical trial testing a combination of Viagra and chemo to treat advanced solid tumors

VCU Massey Cancer Center has developed and opened a Phase 1 clinical trial to study the effects of Viagra in combination with chemotherapy to treat patients with progressive, advanced solid tumors. The trial is a result of previous research conducted at Massey by a group of researchers including physician-scientist Andrew Poklepovic, M.D., who is the leading the trial as its principal investigator. Their research demonstrated that regorafenib (trade name Stivarga), a type of chemotherapy, interacts with Viagra (generic name sildenafil), a medication originally developed for erectile dysfunction, to kill tumor cells significantly better than regorafenib alone.

Continue reading →

Massey researchers identify patients at risk for stem cell transplant complications

Researchers at VCU Massey Cancer Center’s Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival. This first-of-its-kind research continues the efforts of principal investigator Amir Toor, M.D., to understand the immune system as a dynamical system that can be modeled to improve stem cell transplantation.  

Continue reading →

Massey becomes the only medical provider in Richmond to offer Interleukin-2 therapy

VCU Massey Cancer Center is now offering FDA-approved Interleukin-2 (IL-2) therapy for metastatic melanoma and metastatic renal cell carcinoma, making Massey the only medical provider in the Richmond area to offer this service. IL-2 treatment is a type of immunotherapy that stimulates the body’s immune system to recognize and kill tumor cells.

Continue reading →